Regeneron Pharmaceuticals (REGN) ROA - Return on Assets
Current and historical Return on Equity (ROE) values for Regeneron Pharmaceuticals (REGN) over the last 10 years.
|Medical||Medical - Biomedical and Genetics||$41.392B||$4.860B|
|Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)|